Pharmacological targeting of mitochondrial reactive oxygen species counteracts diaphragm weakness in chronic heart failure.

@article{Laitano2016PharmacologicalTO,
  title={Pharmacological targeting of mitochondrial reactive oxygen species counteracts diaphragm weakness in chronic heart failure.},
  author={Orlando Laitano and Bumsoo Ahn and Nikhil Patel and Philip D. Coblentz and Ashley J. Smuder and Jeung-Ki Yoo and Demetra D Christou and Peter J. Adhihetty and Leonardo F Ferreira},
  journal={Journal of applied physiology},
  year={2016},
  volume={120 7},
  pages={733-42}
}
Diaphragm muscle weakness in chronic heart failure (CHF) is caused by elevated oxidants and exacerbates breathing abnormalities, exercise intolerance, and dyspnea. However, the specific source of oxidants that cause diaphragm weakness is unknown. We examined whether mitochondrial reactive oxygen species (ROS) cause diaphragm weakness in CHF by testing the hypothesis that CHF animals treated with a mitochondria-targeted antioxidant have normal diaphragm function. Rats underwent CHF or sham… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 70 references

Similar Papers

Loading similar papers…